Gilead (GILD), Merck (MRK) Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppr

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ACN
3. NVDA
4. MU
5. GOOGL
6. APGE
7. ABBV
8. DFTX
9. USO
10. IBM

Go back to Gilead (GILD), Merck (MRK) Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppr

Gilead Sciences (GILD) Tops Q3 EPS by 94c

October 28, 2021 4:04 PM EDT

Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.65, $0.94 better than the analyst estimate of $1.71. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $6.18 billion.

GUIDANCE:

Gilead Sciences sees FY2021 EPS of $7.90-$8.10, versus the consensus of... More

Merck (MRK) Reports New Data from Phase 2b Clinical Trial Evaluating Efficacy and Safety of Islatravir in Combination With Doravirine

October 27, 2021 6:45 AM EDT

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Week 144 data from the Phase 2b dose-ranging study evaluating the antiretroviral activity, tolerability, and safety of islatravir in combination with doravirine compared to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF)... More

Merck (MRK) Announces License Agreement with The Medicines Patent Pool for Molnipiravir

October 27, 2021 6:00 AM EDT

The Medicines Patent Pool (MPP) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the signing of a voluntary licensing agreement to facilitate affordable global access for molnupiravir, an investigational oral COVID-19 antiviral medicine for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization. This agreement will help create broad access for molnupiravir use in 105 low- and middle-income countries (LMICs) following appropriate regulatory approvals. Merck and Ridgeback Biotherapeutics are jointly developing molnupiravir.

Under the terms of the... More